Guidelines for DOAC use in a low bleeding risk procedure recommend that you ...

Guidelines for DOAC use in a low bleeding risk procedure recommend that you ...

• A. Treat without interrupting medication
• B. Treat only after interrupting
• C. Withhold for 48 hours
• D. Increase dose prior to procedure

Answer: (A)

The main idea here is balancing bleeding risk with the risk of a thromboembolic event. For procedures that are low in bleeding risk, continuing a direct oral anticoagulant is usually the safer choice because interrupting anticoagulation can expose someone to a meaningful risk of stroke or clotting, especially if they have atrial fibrillation or a history of VTE. DOACs act quickly and have a relatively short half-life, so proceeding without stopping maintains protection against clots while the procedure itself tends to have minimal bleeding, and any small amount of extra bleeding can often be controlled with local measures. So, continuing the DOAC during the procedure minimizes thromboembolic risk and avoids the unnecessary bleeding risk that could come from stopping. Withholding for 48 hours is unnecessary for a low-risk procedure and would increase thrombotic risk; delaying or skipping a dose adds complexity without improving safety here. Increasing the dose would raise bleeding risk without any benefit in this context.

The main idea here is balancing bleeding risk with the risk of a thromboembolic event. For procedures that are low in bleeding risk, continuing a direct oral anticoagulant is usually the safer choice because interrupting anticoagulation can expose someone to a meaningful risk of stroke or clotting, especially if they have atrial fibrillation or a history of VTE. DOACs act quickly and have a relatively short half-life, so proceeding without stopping maintains protection against clots while the procedure itself tends to have minimal bleeding, and any small amount of extra bleeding can often be controlled with local measures.

So, continuing the DOAC during the procedure minimizes thromboembolic risk and avoids the unnecessary bleeding risk that could come from stopping. Withholding for 48 hours is unnecessary for a low-risk procedure and would increase thrombotic risk; delaying or skipping a dose adds complexity without improving safety here. Increasing the dose would raise bleeding risk without any benefit in this context.